HRP20160400T1 - Parenteralna primjena tapentadola - Google Patents

Parenteralna primjena tapentadola Download PDF

Info

Publication number
HRP20160400T1
HRP20160400T1 HRP20160400TT HRP20160400T HRP20160400T1 HR P20160400 T1 HRP20160400 T1 HR P20160400T1 HR P20160400T T HRP20160400T T HR P20160400TT HR P20160400 T HRP20160400 T HR P20160400T HR P20160400 T1 HRP20160400 T1 HR P20160400T1
Authority
HR
Croatia
Prior art keywords
preparation according
tapentadol
preparation
pain
dosage form
Prior art date
Application number
HRP20160400TT
Other languages
English (en)
Croatian (hr)
Inventor
Thomas Christoph
Sabine Karine Katrien Inghelbrecht
Roger Carolus Augusta Embrechts
Ulrich Reinhold
Marc Schiller
Eva WULSTEN
Klaus Schiene
Petra Bloms-Funke
Ulrich Feil
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of HRP20160400T1 publication Critical patent/HRP20160400T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20160400TT 2011-03-04 2012-03-02 Parenteralna primjena tapentadola HRP20160400T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161449317P 2011-03-04 2011-03-04
EP11003602 2011-05-03
EP12709792.1A EP2680833B1 (en) 2011-03-04 2012-03-02 Parenteral administration of tapentadol
PCT/EP2012/000905 WO2012119728A1 (en) 2011-03-04 2012-03-02 Parenteral administration of tapentadol

Publications (1)

Publication Number Publication Date
HRP20160400T1 true HRP20160400T1 (hr) 2016-05-20

Family

ID=44653043

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20160400TT HRP20160400T1 (hr) 2011-03-04 2012-03-02 Parenteralna primjena tapentadola

Country Status (22)

Country Link
US (3) US20120225951A1 (enExample)
EP (2) EP3025710A1 (enExample)
JP (4) JP2014510067A (enExample)
KR (2) KR101903351B1 (enExample)
CN (2) CN107088226A (enExample)
AU (2) AU2012224953C1 (enExample)
BR (1) BR112013022213A2 (enExample)
CA (1) CA2828635C (enExample)
CY (1) CY1117426T1 (enExample)
DK (1) DK2680833T3 (enExample)
EA (2) EA028149B1 (enExample)
ES (1) ES2573414T3 (enExample)
HR (1) HRP20160400T1 (enExample)
HU (1) HUE027514T2 (enExample)
IL (1) IL227825A (enExample)
MX (1) MX348831B (enExample)
PL (1) PL2680833T3 (enExample)
PT (1) PT2680833E (enExample)
RS (1) RS54711B1 (enExample)
SI (1) SI2680833T1 (enExample)
WO (1) WO2012119728A1 (enExample)
ZA (1) ZA201306479B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846765B2 (en) 2010-06-15 2014-09-30 Gruenenthal Gmbh Pharmaceutical combination
CN103501773A (zh) 2011-03-04 2014-01-08 格吕伦塔尔有限公司 用于口服给予的他喷他多含水药物制剂
WO2013017233A1 (en) 2011-07-29 2013-02-07 Grünenthal GmbH Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
US9629818B2 (en) 2012-11-01 2017-04-25 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of tapentadol for parenteral administration
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
CN103735500B (zh) * 2014-01-28 2016-01-20 江苏华泽医药科技有限公司 盐酸他喷他多注射液及其制备方法
ES2710299T3 (es) * 2015-03-27 2019-04-24 Gruenenthal Gmbh Formulación estable para la administración parenteral de tapentadol
ES3027562T3 (en) * 2016-09-23 2025-06-16 Gruenenthal Gmbh Stable formulation for parenteral administration of tapentadol
WO2018153947A1 (en) 2017-02-23 2018-08-30 Grünenthal GmbH Tapentadol as local anesthetic
AU2020276619A1 (en) * 2019-05-16 2021-12-16 Nexus Pharmaceuticals, Inc. Compositions comprising ephedrine or an ephedrine salt and methods of making and using same
EP4011369A1 (en) * 2020-12-14 2022-06-15 G.L. Pharma GmbH Aqueous pharmaceutical composition comprising tapentadol tartrate
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334422D0 (en) * 1983-12-23 1984-02-01 Sterwin Ag Composition
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
OA12257A (en) * 2000-04-27 2003-11-06 Pfizer Prod Inc the use of azalide antibiotic compositions for treating or preventing a bacterial or protozoal infection in mammals.
CA2408562A1 (en) * 2000-05-19 2001-11-29 Thomas A. Boyd Dehydroascorbic acid formulations and uses thereof
US6399087B1 (en) * 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
DE10109763A1 (de) * 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
JP4905616B2 (ja) * 2001-04-19 2012-03-28 ライオン株式会社 ソフトコンタクトレンズ用点眼剤
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
US20030191187A1 (en) * 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US20040180915A1 (en) * 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
DE602004007905T2 (de) * 2004-06-28 2008-05-08 Grünenthal GmbH Kristalline Formen von (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochlorid
JP5700904B2 (ja) 2004-07-01 2015-04-15 グリューネンタール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング （１ｒ，２ｒ）−３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノールを含有する乱用防止経口投与形態物
CA2606947A1 (en) * 2005-04-28 2006-11-02 Theraquest Biosciences Llc Methods and compositions for treating pain
JP2009518315A (ja) * 2005-12-02 2009-05-07 エムディーアールエヌエー，インコーポレイテッド グルコース調節ペプチドの上皮透過性を増大させるための製剤処方
PT2012763E (pt) 2006-04-28 2011-04-29 Gruenenthal Gmbh Combinação farmacêutica que compreende 3-(3-dimetilamino-1-etil-2-metil-propil)fenol e um aine
EP2012764B1 (en) 2006-04-28 2011-01-12 Grünenthal GmbH Pharmaceutical combination comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol
CA2656696C (en) * 2006-07-24 2013-06-11 Janssen Pharmaceutica N.V. Preparation of (2r,3r)-3-(3-methoxyphenyl)-n,n,2-trimethylpentanamine
EP1905440A1 (de) * 2006-09-06 2008-04-02 Boehringer Ingelheim Pharma GmbH & Co. KG Verwendung einer pharmazeutischen Zusammensetzung enthaltend ein Anticholinergikum zur Abtötung von Mikroorganismen und zur Behandlung von Atemwegsinfektionen
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
DE102007012165A1 (de) * 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
JP2008266168A (ja) * 2007-04-18 2008-11-06 Teika Seiyaku Kk 眼科用剤
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
KR101607112B1 (ko) 2007-11-23 2016-03-29 그뤼넨탈 게엠베하 타펜타돌 조성물
US8383152B2 (en) 2008-01-25 2013-02-26 Gruenenthal Gmbh Pharmaceutical dosage form
KR101851120B1 (ko) * 2008-09-05 2018-04-23 그뤼넨탈 게엠베하 3-（3-디메틸아미노-1-에틸-2-메틸-프로필）-페놀과 항간질제의 약제학적 병용물
EP2246044A1 (en) * 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
US20100272815A1 (en) 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
CN101961315B (zh) * 2010-09-10 2012-09-05 海南美兰史克制药有限公司 一种门冬氨酸鸟氨酸脂质体注射液

Also Published As

Publication number Publication date
EA024193B1 (ru) 2016-08-31
AU2017202214B2 (en) 2019-02-14
JP2022033863A (ja) 2022-03-02
JP6837944B2 (ja) 2021-03-03
HK1194964A1 (zh) 2014-10-31
EP2680833B1 (en) 2016-03-02
AU2012224953A1 (en) 2013-09-19
MX348831B (es) 2017-06-30
CA2828635C (en) 2020-01-14
RS54711B1 (sr) 2016-08-31
JP2014510067A (ja) 2014-04-24
CN107088226A (zh) 2017-08-25
EA201300990A1 (ru) 2014-02-28
AU2017202214A1 (en) 2017-04-27
EA201600088A1 (ru) 2016-07-29
AU2012224953B2 (en) 2017-01-05
ES2573414T3 (es) 2016-06-07
JP2018021050A (ja) 2018-02-08
DK2680833T3 (en) 2016-05-23
ZA201306479B (en) 2014-05-28
IL227825A0 (en) 2013-09-30
US20200215003A1 (en) 2020-07-09
WO2012119728A1 (en) 2012-09-13
SI2680833T1 (sl) 2016-06-30
CN103501775A (zh) 2014-01-08
CA2828635A1 (en) 2012-09-13
KR20180064568A (ko) 2018-06-14
EA028149B1 (ru) 2017-10-31
JP2023075244A (ja) 2023-05-30
PL2680833T3 (pl) 2016-08-31
EP3025710A1 (en) 2016-06-01
EP2680833A1 (en) 2014-01-08
CY1117426T1 (el) 2017-04-26
KR101903351B1 (ko) 2018-10-04
PT2680833E (pt) 2016-06-09
US20160106688A1 (en) 2016-04-21
MX2013010046A (es) 2013-12-16
KR20140017587A (ko) 2014-02-11
HUE027514T2 (en) 2016-10-28
KR101970468B1 (ko) 2019-04-19
US20120225951A1 (en) 2012-09-06
IL227825A (en) 2017-07-31
BR112013022213A2 (pt) 2017-05-02
AU2012224953C1 (en) 2017-07-13

Similar Documents

Publication Publication Date Title
HRP20160400T1 (hr) Parenteralna primjena tapentadola
US20240238382A1 (en) URI Agonist/Vasodilator
JP2015512392A5 (enExample)
FI3506886T3 (fi) Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä
JP2014510067A5 (enExample)
JP7133070B2 (ja) ベンダムスチンの製剤
HRP20200072T1 (hr) Načini doziranja za spojeve klase ehinokandina
RU2016119746A (ru) Стабильный состав инсулина глулизин
JP2016539921A5 (enExample)
JP2013535422A5 (enExample)
IL291556B2 (en) Methods and compositions for administration of arylsulfatase A to the central nervous system
JP2011511072A5 (enExample)
HRP20191924T1 (hr) Postupci i sastavi za isporuku iduronat-2-sulfataze u cns
HRP20181079T1 (hr) Sirnk i njena primjena u metodama i kompozicijama za liječenje i/ili prevenciju očnih stanja
JP2019142972A5 (enExample)
RU2014148062A (ru) Инъекционная фармацевтическая композиция декскетопрофена и трамадола
EA201491841A1 (ru) Состав эсмолола для парентерального введения
RU2013142835A (ru) Способ лечения ишемического инсульта
HRP20201475T1 (hr) Uporaba neridronske kiseline ili njene soli za liječenje osteoartroze
PH12017501005A1 (en) Injectable formulations of paracetamol
RU2021110820A (ru) Композиции и способы для повышения способности к системной доставке, переносимости и эффективности катионных макроциклических пептидов
NZ761478B2 (en) Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
DOP2005000053A (es) Composicion farmaceutica que comprende acido (2r)-2-propilactanoico como un ingrediente activo
AR088094A1 (es) TRATAMIENTO DE ESCLEROSIS MULTIPLE CON COMBIANACION DE LAQUINIMOD E INTERFERON-b